Latest Press Releases

11.30.22

Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic

11.07.22

Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs

10.24.22

Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic

10.11.22

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022

10.06.22

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022

09.22.22

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

08.09.22

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic

05.24.22

Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

09.29.21

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

09.22.21

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

05.21.21

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

02.17.21

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

10.21.20

Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020

05.06.20

Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660

02.04.20

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

08.21.19

Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research

06.26.19

Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019

06.14.19

Statement: Response to FDA Safety Alert Regarding the Use of Fecal Microbiota for Transplantation

05.17.19

Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted

03.20.19

MICROBIOME HEALTH INDEX™ Platform to be Presented at Gut Microbiota for Health Summit 2019

11.01.18

Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month

10.22.18

Rebiotix MICROBIOME HEALTH INDEX™ Data to be Presented at United European Gastroenterology Annual Conference

10.03.18

Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease States

10.01.18

Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018

06.08.18

MICROBIOME HEALTH INDEX™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018

06.04.18

Rebiotix Microbiota Restoration Therapy™ Products, MICROBIOME HEALTH INDEX™ to Take Center Stage at Digestive Disease Week 2018

06.01.18

Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention

04.24.18

Rebiotix Presents Posters at ECCMID 2018 Highlighting MICROBIOME HEALTH INDEX™ Value Potential and RBX2660 Phase 2 Clinical Program Data

04.05.18

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

03.27.18

Rebiotix’s Lee Jones to Receive TRUST 2018 Courageous Women in Health Care Award

03.12.18

Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe

02.12.18

Rebiotix Develops MICROBIOME HEALTH INDEX™ to Identify Indicators for Microbiome Restoration

01.09.18

Rebiotix Highlights 2017 Achievements and 2018 Objectives

01.05.18

Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy™

01.04.18

Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week

11.29.17

Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms

11.15.17

Rebiotix to Present at 29th Annual Piper Jaffray Healthcare Conference

11.02.17

Rebiotix and the C. diff. Foundation Applaud the State of Minnesota as it Declares November C. Difficile Infection Awareness Month

10.16.17

New Clinical Data and Microbiome Research from Rebiotix’s Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017

10.12.17

Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017

10.04.17

Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix RBX2660 Phase 2 Studies

09.06.17

Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs

08.23.17

Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

08.07.17

Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection

06.20.17

Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer

06.07.17

Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients’ Clinical Success Correlates with Improved Microbiome Diversity

06.01.17

Rebiotix’s Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017

05.04.17

Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

04.11.17

Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile

03.02.17

Rebiotix to Present at Two Investor Conferences

02.06.17

Rebiotix to Present at BIO CEO & Investor Conference

01.04.17

Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection

11.28.16

Rebiotix Appoints Ken F. Blount, Ph.D., Head of External Research

11.16.16

Rebiotix to Present at Piper Jaffray 28th Annual Healthcare Conference

10.17.16

Data from Rebiotix’s Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016

10.11.16

Rebiotix Receives Patent from the USPTO for Microbiota Restoration Therapy

09.06.16

Rebiotix to Present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference

01.11.16

Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms

12.14.15

Rebiotix and McMaster Children’s Hospital Announce First Patient Treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis

12.01.15

Rebiotix Named 2015 Tekne Award Winner

11.18.15

Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection

10.12.15

Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection

12.16.14

Rebiotix Announces First-Ever Randomized Study of a Microbiota-based Drug for Recurrent Clostridium difficile Infection under an FDA IND

10.20.14

Rebiotix Presents Additional Results of PUNCH™ CD Study of Microbiota-based Drug Candidate for Recurrent C. difficile Infection at ACG

10.09.14

Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective

09.17.14

PUNCH™ CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014

08.04.14

Rebiotix Inc. Receives $25M for Series B Funding

06.03.14

Rebiotix to Present at 2014 BIO International Conference

01.13.14

Rebiotix Completes Enrollment in Phase 2 Clinical Trial of New Drug for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea

10.31.13

Rebiotix Wins 2013 Leaders in Health Care Award

10.15.13

Rebiotix Begins Clinical Trial of Therapy for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea

09.05.13

Rebiotix Named Finalist for 2013 Leaders in Health Care Awards

07.29.13

Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy

06.24.13

FDA Grants Fast Track Designation to Rebiotix for its Microbiota Product for Recurrent Clostridium difficile Infection

06.04.13

Rebiotix Inc. Hires Ryan Gordon as Vice President

05.01.13

Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors